Rhythm Pharmaceuticals CHRO Exercises Options, Sells 3,350 Shares

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported an option exercise and share sale involving the company’s common stock.

Rhea-AI Filing Summary

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported an option exercise and share sale involving the company’s common stock.

On 12/11/2025, she exercised 3,350 stock options at $27.35 per share, acquiring 3,350 shares, and then sold 3,350 common shares at $111 per share under a Rule 10b5-1 trading plan adopted on August 7, 2025. Following these transactions, she directly held 20,814 common shares and 8,375 stock options expiring on 01/31/2033, which were granted on 02/01/2023 and vest in 16 substantially equal installments based on continued service.

Insider Trade Summary

Exercise and Sale: 3,350 shares ($280K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Cramer Pamela J.

Role Chief Human Resources Officer

Sold 3,350 shs ($372K)

Approx. gross sale proceeds $372K

Approx. exercise cost $92K

Approx. pre-tax spread $280K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	3,350	$0.00	$0.00
Exercise	Common Stock	3,350	$27.35	$92K
Sale	Common Stock	3,350	$111.00	$372K

Holdings After Transaction: Stock Options (Right to Buy) — 8,375 contracts (Direct); Common Stock — 20,814 shares (Direct)

Footnotes (2)

1. F1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
2. F2. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rhythm Pharmaceuticals (RYTM) report for its CHRO?

Pamela J. Cramer, Chief Human Resources Officer, exercised 3,350 stock options at $27.35 and sold 3,350 common shares at $111 on 12/11/2025.

Was the RYTM insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale of 3,350 common shares was effected under a Rule 10b5-1 trading plan adopted by Pamela J. Cramer on August 7, 2025.

How many Rhythm Pharmaceuticals shares does the reporting person own after the transaction?

After the reported transactions, Pamela J. Cramer beneficially owned 20,814 shares of Rhythm Pharmaceuticals common stock directly.

How many stock options does the Rhythm Pharmaceuticals CHRO hold after this Form 4?

Following the transactions, she held 8,375 stock options with an expiration date of 01/31/2033.

What are the key terms of the Rhythm Pharmaceuticals stock options exercised?

The options have an exercise price of $27.35 per share, were granted on 02/01/2023, and vest in 16 substantially equal installments based on three-month service periods.

At what price were the Rhythm Pharmaceuticals shares sold in this insider transaction?

The 3,350 common shares were sold at a price of $111 per share on 12/11/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cramer Pamela J.

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		3,350	A	$27.35	24,164	D
Common Stock	12/11/2025		S(1)		3,350	D	$111	20,814	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$27.35	12/11/2025		M			3,350	(2)	01/31/2033	Common Stock	3,350	$0	8,375	D

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.

2. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.